| The genomic landscape of hypodiploid acute lymphoblastic leukemia L Holmfeldt, L Wei, E Diaz-Flores, M Walsh, J Zhang, L Ding, ... Nature genetics 45 (3), 242-252, 2013 | 784 | 2013 |
| CREBBP mutations in relapsed acute lymphoblastic leukaemia CG Mullighan, J Zhang, LH Kasper, S Lerach, D Payne-Turner, ... Nature 471 (7337), 235-239, 2011 | 695 | 2011 |
| Differential metabolism of gefitinib and erlotinib by human cytochrome P450 enzymes J Li, M Zhao, P He, M Hidalgo, SD Baker Clinical Cancer Research 13 (12), 3731-3737, 2007 | 338 | 2007 |
| Irinotecan pathway genotype analysis to predict pharmacokinetics RHJ Mathijssen, S Marsh, MO Karlsson, R Xie, SD Baker, J Verweij, ... Clinical cancer research 9 (9), 3246-3253, 2003 | 323 | 2003 |
| Role of body surface area in dosing of investigational anticancer agents in adults, 1991–2001 SD Baker, J Verweij, EK Rowinsky, RC Donehower, JHM Schellens, ... Journal of the National Cancer Institute 94 (24), 1883-1888, 2002 | 322 | 2002 |
| Homocysteine and methylmalonic acid: markers to predict and avoid toxicity from pemetrexed therapy C Niyikiza, SD Baker, DE Seitz, JM Walling, K Nelson, JJ Rusthoven, ... Molecular cancer therapeutics 1 (7), 545-552, 2002 | 321 | 2002 |
| An epidermal growth factor receptor intron 1 polymorphism mediates response to epidermal growth factor receptor inhibitors ML Amador, D Oppenheimer, S Perea, A Maitra, G Cusati, ... Cancer Research 64 (24), 9139-9143, 2004 | 310 | 2004 |
| Absorption, Metabolism, and Excretion of 14C-Temozolomide following Oral Administration to Patients with Advanced Cancer SD Baker, M Wirth, P Statkevich, P Reidenberg, K Alton, SE Sartorius, ... Clinical Cancer Research 5 (2), 309-317, 1999 | 307 | 1999 |
| A phase I dose escalation and bioavailability study of oral sodium phenylbutyrate in patients with refractory solid tumor malignancies J Gilbert, SD Baker, MK Bowling, L Grochow, WD Figg, Y Zabelina, ... Clinical Cancer Research 7 (8), 2292-2300, 2001 | 301 | 2001 |
| Pharmacogenetics of ABCG2 and adverse reactions to gefitinib G Cusatis, V Gregorc, J Li, A Spreafico, RG Ingersoll, J Verweij, ... Journal of the National Cancer Institute 98 (23), 1739-1742, 2006 | 284 | 2006 |
| Interaction of imatinib with human organic ion carriers S Hu, RM Franke, KK Filipski, C Hu, SJ Orwick, EA De Bruijn, H Burger, ... Clinical Cancer Research 14 (10), 3141-3148, 2008 | 263 | 2008 |
| Tumor targeting by covalent conjugation of a natural fatty acid to paclitaxel MO Bradley, NL Webb, FH Anthony, P Devanesan, PA Witman, ... Clinical Cancer Research 7 (10), 3229-3238, 2001 | 263 | 2001 |
| Crenolanib is active against models of drug-resistant FLT3-ITD− positive acute myeloid leukemia EI Zimmerman, DC Turner, J Buaboonnam, S Hu, S Orwick, MS Roberts, ... Blood, The Journal of the American Society of Hematology 122 (22), 3607-3615, 2013 | 210 | 2013 |
| A phase I evaluation of multitargeted antifolate (MTA, LY231514), administered every 21 days, utilizing the modified continual reassessment method for dose escalation DA Rinaldi, JG Kuhn, HA Burris, FA Dorr, G Rodriguez, SG Eckhardt, ... Cancer chemotherapy and pharmacology 44, 372-380, 1999 | 208 | 1999 |
| Association of variant ABCG2 and the pharmacokinetics of epidermal growth factor receptor tyrosine kinase inhibitors in cancer patients J Li, G Cusatis, J Brahmer, A Sparreboom, RW Robey, SE Bates, ... Cancer biology & therapy 6 (3), 432-438, 2007 | 206 | 2007 |
| Phase I pharmacokinetic and pharmacodynamic study of the multikinase inhibitor sorafenib in combination with clofarabine and cytarabine in pediatric relapsed/refractory leukemia H Inaba, JE Rubnitz, E Coustan-Smith, L Li, BD Furmanski, GP Mascara, ... Journal of clinical oncology 29 (24), 3293, 2011 | 198 | 2011 |
| Interaction of the multikinase inhibitors sorafenib and sunitinib with solute carriers and ATP-binding cassette transporters S Hu, Z Chen, R Franke, S Orwick, M Zhao, MA Rudek, A Sparreboom, ... Clinical Cancer Research 15 (19), 6062-6069, 2009 | 197 | 2009 |
| Pharmacogenetic pathway analysis of docetaxel elimination SD Baker, J Verweij, GA Cusatis, RH Van Schaik, S Marsh, SJ Orwick, ... Clinical Pharmacology & Therapeutics 85 (2), 155-163, 2009 | 195 | 2009 |
| Evaluation of alternate size descriptors for dose calculation of anticancer drugs in the obese A Sparreboom, AC Wolff, RHJ Mathijssen, E Chatelut, EK Rowinsky, ... Journal of clinical oncology 25 (30), 4707-4713, 2007 | 193 | 2007 |
| Efficacy of retinoids in IKZF1-mutated BCR-ABL1 acute lymphoblastic leukemia ML Churchman, J Low, C Qu, EM Paietta, LH Kasper, Y Chang, ... Cancer cell 28 (3), 343-356, 2015 | 189 | 2015 |
